Correlation Between Serum Free Triiodothyronine Levels and Risk Stratification in Chinese Patients with Acute Coronary Syndrome Receiving Percutaneous Coronary Intervention

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Sep 21

PMID 32954890

Citations 1

Authors

Huiying Li

Chunlin Li

Yongyi Bai

Zhao Wang

Man Li

Yulun Cai

Wenli Zhou

Baohua Zhang

Hongbin Liu

Affiliations

Soon will be listed here.

Abstract

Objective: Low serum free triiodothyronine (FT3) levels are associated with the occurrence of coronary heart disease and with the prognosis of cardiovascular diseases. This study aimed to investigate the relationship between FT3 levels and risk stratification in Chinese Han patients with acute coronary syndrome (ACS) receiving percutaneous coronary intervention (PCI) treatment.

Methods: Plasma FT3 levels and other parameters were measured in 191 patients with ACS who received PCI. The risk of adverse cardiovascular events was assessed using the Age, Creatinine, and Ejection Fraction (ACEF) score.

Results: FT3 levels were significantly lower in the high-risk group than in the medium- and low-risk groups. Serum FT3 levels were negatively linearly correlated with the ACEF score (r = -0.590). Stepwise regression analysis showed a negative correlation between FT3 levels and the risk of adverse cardiovascular events as measured by the ACEF score (standardized β = -0.261).

Conclusion: Serum FT3 levels are negatively related to risk stratification in patients with ACS. Serum FT3 levels may be used as a potential predictor for adverse outcomes of patients with ACS undergoing PCI.

Citing Articles

The ratio of HDL-C to apoA-I interacts with free triiodothyronine to modulate coronary artery disease risk.

Li L, Cai G, Lu W, Li F, Yu L, Xiao J BMC Cardiovasc Disord. 2021; 21(1):504.

PMID: 34666674 PMC: 8524928. DOI: 10.1186/s12872-021-02316-8.

References

Han C, He X, Xia X, Li Y, Shi X, Shan Z . Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(8):e0135233. PMC: 4535849. DOI: 10.1371/journal.pone.0135233. View

Angelin B, Kristensen J, Eriksson M, Carlsson B, Klein I, Olsson A . Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J Intern Med. 2014; 277(3):331-342. DOI: 10.1111/joim.12261. View

Klemperer J, Klein I, Gomez M, Helm R, Ojamaa K, Thomas S . Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995; 333(23):1522-7. DOI: 10.1056/NEJM199512073332302. View

Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Agha S, Rashad M, Laskar S . Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J. 2009; 157(2):299-305. DOI: 10.1016/j.ahj.2008.10.007. View

Zhang B, Peng W, Wang C, Li W, Xu Y . A low fT3 level as a prognostic marker in patients with acute myocardial infarctions. Intern Med. 2012; 51(21):3009-15. DOI: 10.2169/internalmedicine.51.7902. View

Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G . Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation. 2009; 119(24):3053-61. DOI: 10.1161/CIRCULATIONAHA.108.842393. View

Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M . Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015; 36(19):1163-70. DOI: 10.1093/eurheartj/ehu505. View

Di Serafino L, Borgia F, Maeremans J, Pyxaras S, De Bruyne B, Wijns W . The age, creatinine, and ejection fraction score to risk stratify patients who underwent percutaneous coronary intervention of coronary chronic total occlusion. Am J Cardiol. 2014; 114(8):1158-64. DOI: 10.1016/j.amjcard.2014.07.034. View

Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver J . The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007; 92(5):1715-23. DOI: 10.1210/jc.2006-1869. View

10.

Papaioannou G, Lagasse M, Mather J, Thompson P . Treating hypothyroidism improves endothelial function. Metabolism. 2004; 53(3):278-9. DOI: 10.1016/j.metabol.2003.10.003. View

11.

Coceani M, Iervasi G, Pingitore A, Carpeggiani C, LAbbate A . Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol. 2009; 32(7):380-5. PMC: 6653244. DOI: 10.1002/clc.20574. View

12.

Johansson L, Rudling M, Scanlan T, Lundasen T, Webb P, Baxter J . Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A. 2005; 102(29):10297-302. PMC: 1177400. DOI: 10.1073/pnas.0504379102. View

13.

Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M . Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003; 107(5):708-13. DOI: 10.1161/01.cir.0000048124.64204.3f. View

14.

Ranucci M, Pistuddi V, Scolletta S, De Vincentiis C, Menicanti L . The ACEF II Risk Score for cardiac surgery: updated but still parsimonious. Eur Heart J. 2017; 39(23):2183-2189. DOI: 10.1093/eurheartj/ehx228. View

15.

Aronson D, Mittleman M, Burger A . Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med. 2004; 116(7):466-73. DOI: 10.1016/j.amjmed.2003.11.014. View

16.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

17.

Wykrzykowska J, Garg S, Onuma Y, de Vries T, Goedhart D, Morel M . Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial. Circ Cardiovasc Interv. 2011; 4(1):47-56. DOI: 10.1161/CIRCINTERVENTIONS.110.958389. View

18.

Bakker O, Hudig F, Meijssen S, Wiersinga W . Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun. 1998; 249(2):517-21. DOI: 10.1006/bbrc.1998.9174. View

19.

Sinha R, Singh B, Yen P . Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018; 14(5):259-269. PMC: 6013028. DOI: 10.1038/nrendo.2018.10. View

20.

Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L . Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003; 88(8):3731-7. DOI: 10.1210/jc.2003-030039. View